The Challenge of Sustainable Access to Telemonitoring Tools for People with Diabetes in Europe: Lessons from COVID-19 and Beyond.
Pratik Choudhary,Virginia Bellido,Matthijs Graner,Bernd Altpeter,Americo Cicchetti,Isabelle Durand-Zaleski,Finn Børlum Kristensen +6 more
TLDR
In this article, the benefits of and challenges to wider application of telemedicine and telemonitoring in the post-pandemic future, with the aim to ensure that the value of these eHealth services is provided to patients, healthcare providers and health systems.Abstract:
Telemedicine in diabetes care has been evolving over several years, particularly since the advent of cloud-connected technologies for diabetes management, such as glucose monitoring devices, including continuous glucose monitoring (CGM) systems, that facilitate sharing of glucose data between people with diabetes and their healthcare professionals in near-real time. Extreme social distancing and shielding in place for vulnerable patients during the COVID-19 pandemic has created both the challenge and the opportunity to provide care at a distance on a large scale. Available evidence suggests that glucose control has in fact improved during this period for people with diabetes who are able to use CGM devices for remote glucose monitoring. The development of telemedicine as part of the standard of care in diabetes faces significant challenges in the European context, particularly in terms of providing consistent and effective care at a distance to large populations of patients while using robust systems that can be supported by large regional and national healthcare services. These challenges include a fragmented approach to healthcare technology assessment and reimbursement, lack of eHealth education and literacy, particularly amongst healthcare professionals, lack of data integration, as well as concerns about electronic health records, patient consent and privacy. Here we review the benefits of and challenges to wider application of telemedicine and telemonitoring in the post-pandemic future, with the aim to ensure that the value of these eHealth services is provided to patients, healthcare providers and health systems.read more
Citations
More filters
Journal ArticleDOI
Benefits of a Switch from Intermittently Scanned Continuous Glucose Monitoring (isCGM) to Real-Time (rt) CGM in Diabetes Type 1 Suboptimal Controlled Patients in Real-Life: A One-Year Prospective Study §
TL;DR: In this article, the ambulatory glucose profile (AGP) in such patients after switching from Free Style Libre 1 (FSL1) to Dexcom G4 (DG4) biosensors over 1 year was evaluated.
Journal ArticleDOI
Telehealth for people with diabetes: poised for a new approach
TL;DR: Limbert et al. as mentioned in this paper proposed a hybrid model of in-person and telehealth for patients with type 1 diabetes during the COVID-19 pandemic, which showed significant improvements in outcomes in several disease groups that included diabetes.
Journal ArticleDOI
Effects of Mobile Application Program (App)-Assisted Health Education on Preventive Behaviors and Cancer Literacy among Women with Cervical Intraepithelial Neoplasia.
TL;DR: In this article, the effects of health education on preventive behaviors and cancer literacy among women with cervical intraepithelial neoplasia (CIN) were compared with traditional book-form health education.
Journal ArticleDOI
Monthly video consultation for children and adolescents with type 1 diabetes mellitus during the COVID-19 pandemic
Simone von Sengbusch,Julia Schneidewind,Jessica Bokelmann,N. Scheffler,Bettina Bertram,Fabian Simon Frielitz,Olaf Hiort,Karin Lange +7 more
TL;DR: In this article , the impact of telemedical care for children and adolescents with type 1 diabetes by monthly video consultations on metabolic control and parents' treatment satisfaction and disease-specific burden during the COVID-19 pandemic was explored.
Journal ArticleDOI
Efficacy of the mHealth application in patients with type 2 diabetes transitioning from inpatient to outpatient care: a randomized controlled clinical trial.
Diana Cristina Henao,Fabian Mauricio León Vargas,Oscar Mauricio Muñoz,Oscar David Lucero,Maira García Jaramillo,Arantza Aldea,Clare Martin,Luis Miguel Rodríguez Hortúa,Claudia Patricia Rubio Reyes,María Alejandra Páez Hortúa,Martín Rondón,Ana María Gómez +11 more
TL;DR: In this article , the efficacy and safety of patient management with and without mHealth was compared at the 3-month follow-up, and the mean HbA1c level was significantly lower in the mHealth group than standard care.
References
More filters
Journal ArticleDOI
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Wang et al. as discussed by the authors used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death, including older age, high SOFA score and d-dimer greater than 1 μg/mL.
Journal ArticleDOI
Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020.
Erin K. Stokes,Laura D. Zambrano,Kayla N. Anderson,Ellyn P. Marder,Kala M. Raz,Suad El Burai Felix,Yunfeng Tie,Kathleen E. Fullerton +7 more
TL;DR: The COVID-19 pandemic continues to be severe, particularly in certain population groups, and the need to build on current efforts to collect and analyze case data, especially among those with underlying health conditions is underscored.
Journal ArticleDOI
Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
Roy W. Beck,Tonya D Riddlesworth,Katrina J. Ruedy,Andrew J. Ahmann,Richard M. Bergenstal,Stacie Haller,Craig Kollman,Davida F. Kruger,Janet B. McGill,William H. Polonsky,Elena Toschi,Howard Wolpert,David Price +12 more
TL;DR: Among adults with type 1 diabetes who used multiple daily insulin injections, the use of CGM compared with usual care resulted in a greater decrease in HbA1c level during 24 weeks.
Journal ArticleDOI
Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial
TL;DR: Novel flash glucose testing reduced the time adults with well controlled type 1 diabetes spent in hypoglycaemia in the intervention group, and future studies are needed to assess the effectiveness of this technology in patients with less well controlled diabetes and in younger age groups.
Journal ArticleDOI
Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study.
Emma Barron,Chirag Bakhai,Partha Kar,Andy Weaver,Dominique Bradley,Hassan Ismail,Peter Knighton,Naomi Holman,Kamlesh Khunti,Naveed Sattar,Nicholas J. Wareham,Bob Young,Jonathan Valabhji,Jonathan Valabhji,Jonathan Valabhji +14 more
TL;DR: The results of this nationwide analysis in England show that type 1 and type 2 diabetes were both independently associated with a significant death with COVID-19, and the effects were attenuated to ORs of 2·86 (2·58–3·18) for type 1 diabetes and 1·80 (1·75–1·86) fortype 2 diabetes when also adjusted for previous hospital admissions with coronary heart disease, cerebrovascular disease, or heart failure.